Compare IDEXX Laboratories, Inc. (IDXX) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs ArcelorMittal SA — how do they compare? IDEXX Laboratories, Inc. trades at $573.57 (market cap $46.22B), while ArcelorMittal SA trades at $74.3 (market cap $55.88B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and ArcelorMittal SA pays a 0.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MT | |
|---|---|---|
Market Cap | $46.22B | $55.88B |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $75.35 |
52-Week Low | $526.44 | $32.44 |
Enterprise Value | $47.12B | $65.45B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
ArcelorMittal (MT) trades at $73.90, up 0.83% with bullish technical signals and strong institutional support. The stock shows improving fundamentals with Q2 2026 revenue growth despite an earnings miss, while maintaining stable dividends. Recent news highlights strategic partnerships and European business recovery prospects.
Outlook remains cautiously optimistic with 50% analyst buy ratings, though risks include cyclical steel demand and margin pressures. The current P/E of 30.97 appears elevated relative to historical norms, requiring sustained earnings growth to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
